Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Commensal microflora-induced T cell responses mediate progressive neurodegeneration in glaucoma.

Chen H, Cho KS, Vu THK, Shen CH, Kaur M, Chen G, Mathew R, McHam ML, Fazelat A, Lashkari K, Au NPB, Tse JKY, Li Y, Yu H, Yang L, Stein-Streilein J, Ma CHE, Woolf CJ, Whary MT, Jager MJ, Fox JG, Chen J, Chen DF.

Nat Commun. 2018 Aug 10;9(1):3209. doi: 10.1038/s41467-018-05681-9.

2.

Digital PCR-based T Cell Quantification Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.

de Lange M, Nell RJ, Lalai RN, Versluis M, Jordanova ES, Luyten GP, Jager MJ, van der Burg SH, Zoutman WH, van Hall T, van der Velden PA.

Mol Cancer Res. 2018 Aug 9. pii: molcanres.0114.2018. doi: 10.1158/1541-7786.MCR-18-0114. [Epub ahead of print]

PMID:
30093564
3.

Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.

Szalai E, Jiang Y, van Poppelen NM, Jager MJ, de Klein A, Kilic E, Grossniklaus HE.

JAMA Ophthalmol. 2018 Aug 2. doi: 10.1001/jamaophthalmol.2018.2986. [Epub ahead of print]

PMID:
30073324
4.

The Cancer Genome Atlas Project: An Integrated Molecular View of Uveal Melanoma.

Jager MJ, Brouwer NJ, Esmaeli B.

Ophthalmology. 2018 Aug;125(8):1139-1142. doi: 10.1016/j.ophtha.2018.03.011. No abstract available.

PMID:
30032793
5.

Periocular CO2 laser resurfacing: severe ocular complications from multiple unintentional laser impacts on the protective metal eye shields.

van Gemert MJC, Bloemen PR, Wang WY, van der Geld CWM, Nuijts RMMA, Hortoglu H, Wolkerstorfer A, de Bruin DM, van Leeuwen TG, Neumann HAM, Jager MJ.

Lasers Surg Med. 2018 Jun 8. doi: 10.1002/lsm.22951. [Epub ahead of print]

PMID:
29882233
6.

Lack of tumour pigmentation in conjunctival melanoma is associated with light iris colour and worse prognosis.

Brouwer NJ, Marinkovic M, Luyten GPM, Shields CL, Jager MJ.

Br J Ophthalmol. 2018 May 18. pii: bjophthalmol-2018-312018. doi: 10.1136/bjophthalmol-2018-312018. [Epub ahead of print]

PMID:
29777046
7.

Neuroinflammation and microglia in glaucoma: time for a paradigm shift.

Wei X, Cho KS, Thee EF, Jager MJ, Chen DF.

J Neurosci Res. 2018 May 18. doi: 10.1002/jnr.24256. [Epub ahead of print] Review.

PMID:
29775216
8.

Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.

Cao J, Pontes KC, Heijkants RC, Brouwer NJ, Groenewoud A, Jordanova ES, Marinkovic M, van Duinen S, Teunisse AF, Verdijk RM, Snaar-Jagalska E, Jochemsen AG, Jager MJ.

J Pathol. 2018 Aug;245(4):433-444. doi: 10.1002/path.5094. Epub 2018 Jun 23.

PMID:
29732557
9.

Characterization of a conjunctival melanoma cell line CM-AS16, newly-established from a metastatic Han Chinese patient.

Li Y, Shang Q, Li P, Cao J, Zhu L, Jager MJ, Fan X, Ge S, Jia R.

Exp Eye Res. 2018 Aug;173:51-63. doi: 10.1016/j.exer.2018.03.030. Epub 2018 Apr 10.

PMID:
29653142
10.

HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status.

Cao J, Brouwer NJ, Jordanova ES, Marinkovic M, van Duinen SG, de Waard NE, Ksander BR, Mulder A, Claas FHJ, Heemskerk MHM, Jager MJ.

Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):1005-1015. doi: 10.1167/iovs.17-23209.

PMID:
29450544
11.

Pimasertib-associated ophthalmological adverse events.

van Dijk EHC, Kruit WHJ, Jager MJ, Luyten GPM, Vingerling JR, Boon CJF.

Acta Ophthalmol. 2018 Jan 16. doi: 10.1111/aos.13677. [Epub ahead of print]

PMID:
29338133
12.

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE.

Cancer Cell. 2018 Jan 8;33(1):151. doi: 10.1016/j.ccell.2017.12.013. No abstract available.

13.

Introducing Johanna M. Seddon, the 2017 Recipient of the Mildred Weisenfeld Award.

Jager MJ.

Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6510-6512. doi: 10.1167/iovs.17-23542. No abstract available.

PMID:
29288271
14.

Evaluation of (fli:GFP) Casper Zebrafish Embryos as a Model for Human Conjunctival Melanoma.

Pontes KCS, Groenewoud A, Cao J, Ataide LMS, Snaar-Jagalska E, Jager MJ.

Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6065-6071. doi: 10.1167/iovs.17-22023.

PMID:
29204645
15.

Treatment of conjunctival melanoma in a Dutch referral centre.

Brouwer NJ, Marinkovic M, van Duinen SG, Bleeker JC, Jager MJ, Luyten GPM.

Br J Ophthalmol. 2017 Nov 9. pii: bjophthalmol-2017-311082. doi: 10.1136/bjophthalmol-2017-311082. [Epub ahead of print]

PMID:
29122819
16.

Genetic prognostication in uveal melanoma.

Dogrusöz M, Jager MJ.

Acta Ophthalmol. 2017 Nov 4. doi: 10.1111/aos.13580. [Epub ahead of print] Review.

PMID:
29105334
17.

Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma.

Brouwer NJ, Haanen JBAG, Jager MJ.

Ocul Oncol Pathol. 2017 Sep;3(3):188-192. doi: 10.1159/000455150. Epub 2017 Feb 2.

18.

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.

Cao J, Brouwer NJ, Richards KE, Marinkovic M, van Duinen S, Hurkmans D, Verdegaal EME, Jordanova ES, Jager MJ.

Oncotarget. 2017 May 20;8(33):54722-54734. doi: 10.18632/oncotarget.18039. eCollection 2017 Aug 15.

19.

Multiple Pigmented Conjunctival Lesions following Intravitreal Injections in a Patient with Uveal Melanoma.

Brouwer NJ, Luyten GPM, van Duinen SG, Jager MJ, Marinkovic M.

Ocul Oncol Pathol. 2017 Jul;3(2):113-116. doi: 10.1159/000452447. Epub 2016 Nov 9.

20.

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE.

Cancer Cell. 2017 Aug 14;32(2):204-220.e15. doi: 10.1016/j.ccell.2017.07.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):151.

21.

GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi.

Vader MJC, Madigan MC, Versluis M, Suleiman HM, Gezgin G, Gruis NA, Out-Luiting JJ, Bergman W, Verdijk RM, Jager MJ, van der Velden PA.

Br J Cancer. 2017 Sep 5;117(6):884-887. doi: 10.1038/bjc.2017.259. Epub 2017 Aug 15.

PMID:
28809862
22.

Corrigendum : Uveal Melanoma Treatment and Prognostication.

Dogrusöz M, Jager MJ, Damato B.

Asia Pac J Ophthalmol (Phila). 2017 May-Jun;6(3):305. doi: 10.22608/APO.201734. No abstract available.

23.

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ.

JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729.

24.

Uveal Melanoma Treatment and Prognostication.

Dogrusöz M, Jager MJ, Damato B.

Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr;6(2):186-196. doi: 10.22608/APO.201734. Review. Erratum in: Asia Pac J Ophthalmol (Phila). 2017 May-Jun;6(3):305.

25.

Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases.

Jager MJ, Dogrusöz M, Woodman SE.

Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr;6(2):179-185. doi: 10.22608/APO.201782. Review.

26.

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Gezgin G, Dogrusöz M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, Walter V, Verdijk RM, van Hall T, van der Burg SH, Jager MJ.

Cancer Immunol Immunother. 2017 Jul;66(7):903-912. doi: 10.1007/s00262-017-1991-1. Epub 2017 Apr 8.

27.

The Prognostic Value of AJCC Staging in Uveal Melanoma Is Enhanced by Adding Chromosome 3 and 8q Status.

Dogrusöz M, Bagger M, van Duinen SG, Kroes WG, Ruivenkamp CA, Böhringer S, Andersen KK, Luyten GP, Kiilgaard JF, Jager MJ.

Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):833-842. doi: 10.1167/iovs.16-20212.

PMID:
28159971
28.

Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).

Jager MJ, Magner JA, Ksander BR, Dubovy SR.

Trans Am Ophthalmol Soc. 2016 Aug;114:T5. Review.

29.

Induction of Chemokine Secretion and Monocyte Migration by Human Choroidal Melanocytes in Response to Proinflammatory Cytokines.

Jehs T, Faber C, Udsen MS, Jager MJ, Clark SJ, Nissen MH.

Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6568-6579. doi: 10.1167/iovs.15-18524.

PMID:
27918831
30.

Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.

de Leede EM, Burgmans MC, Kapiteijn E, Luyten GP, Jager MJ, Tijl FG, Hartgrink HH, Grünhagen DJ, Rothbarth J, van de Velde CJ, Verhoef C, Vahrmeijer AL.

Melanoma Res. 2016 Dec;26(6):588-594.

PMID:
27513071
31.

Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes.

van Essen TH, van Pelt SI, Bronkhorst IH, Versluis M, Némati F, Laurent C, Luyten GP, van Hall T, van den Elsen PJ, van der Velden PA, Decaudin D, Jager MJ.

PLoS One. 2016 Oct 20;11(10):e0164292. doi: 10.1371/journal.pone.0164292. eCollection 2016.

32.

CT and MR Imaging in the Diagnosis of Scleritis.

Diogo MC, Jager MJ, Ferreira TA.

AJNR Am J Neuroradiol. 2016 Dec;37(12):2334-2339. Epub 2016 Jul 21.

33.

Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Cao J, Heijkants RC, Jochemsen AG, Dogrusöz M, de Lange MJ, van der Velden PA, van der Burg SH, Jager MJ, Verdijk RM.

Oncotarget. 2016 Jul 22;8(35):58021-58036. doi: 10.18632/oncotarget.10770. eCollection 2017 Aug 29.

34.

Analysis of monosomy-3 in immunomagnetically isolated circulating melanoma cells in uveal melanoma patients.

Tura A, Merz H, Reinsberg M, Lüke M, Jager MJ, Grisanti S, Lüke J.

Pigment Cell Melanoma Res. 2016 Sep;29(5):583-9. doi: 10.1111/pcmr.12507.

PMID:
27390171
35.

Animal Eye Models for Uveal Melanoma.

Cao J, Jager MJ.

Ocul Oncol Pathol. 2015 Apr;1(3):141-50. doi: 10.1159/000370152. Epub 2015 Apr 9. Review.

36.

Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies.

Pont MJ, Honders MW, Kremer AN, van Kooten C, Out C, Hiemstra PS, de Boer HC, Jager MJ, Schmelzer E, Vries RG, Al Hinai AS, Kroes WG, Monajemi R, Goeman JJ, Böhringer S, Marijt WA, Falkenburg JH, Griffioen M.

PLoS One. 2016 May 12;11(5):e0155165. doi: 10.1371/journal.pone.0155165. eCollection 2016.

37.

Embryonic Zebrafish: Different Phenotypes after Injection of Human Uveal Melanoma Cells.

van der Ent W, Burrello C, de Lange MJ, van der Velden PA, Jochemsen AG, Jager MJ, Snaar-Jagalska BE.

Ocul Oncol Pathol. 2015 Apr;1(3):170-81. doi: 10.1159/000370159. Epub 2015 Apr 9. Review.

38.

Introducing Anneke I. den Hollander, the Recipient of the 2015 Cogan Award.

Jager MJ.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1376-7. doi: 10.1167/iovs.16-19380. No abstract available.

PMID:
27010694
39.

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW.

Clin Cancer Res. 2016 Mar 1;22(5):1234-42. doi: 10.1158/1078-0432.CCR-15-2071.

40.

Donor sclera-wrapped acrylic orbital implants following enucleation: experience in 179 patients in the Netherlands.

Jongman HP, Marinkovic M, Notting I, Koetsier L, Swart W, Schalij-Delfos NE, Bleeker J, Jager MJ, Luyten GP.

Acta Ophthalmol. 2016 May;94(3):253-6. doi: 10.1111/aos.12960. Epub 2016 Feb 23.

41.

The Pediatric Choroidal and Ciliary Body Melanoma Study: A Survey by the European Ophthalmic Oncology Group.

Al-Jamal RT, Cassoux N, Desjardins L, Damato B, Konstantinidis L, Coupland SE, Heimann H, Petrovic A, Zografos L, Schalenbourg A, Velazquez-Martin JP, Krema H, Bogdali A, Markiewicz A, Romanowska-Dixon B, Metz CH, Biewald E, Bornfeld N, Kiratli H, Bronkhorst IH, Jager MJ, Marinkovic M, Fili M, Seregard S, Frenkel S, Pe'er J, Salvi SM, Rennie IG, Rospond-Kubiak I, Kociecki J, Kiilgaard JF, Heegaard S, Cohen VM, Sagoo MS, Amiryan A, Saakyan S, Eide N, Krohn J, Midena E, Parrozzani R, Grange JD, Kilic E, Blasi MA, Saornil MA, Kivelä TT.

Ophthalmology. 2016 Apr;123(4):898-907. doi: 10.1016/j.ophtha.2015.12.024. Epub 2016 Feb 4.

PMID:
26854035
42.

Biocompatibility of a fish scale-derived artificial cornea: Cytotoxicity, cellular adhesion and phenotype, and in vivo immunogenicity.

van Essen TH, van Zijl L, Possemiers T, Mulder AA, Zwart SJ, Chou CH, Lin CC, Lai HJ, Luyten GPM, Tassignon MJ, Zakaria N, El Ghalbzouri A, Jager MJ.

Biomaterials. 2016 Mar;81:36-45. doi: 10.1016/j.biomaterials.2015.11.015. Epub 2015 Dec 1.

PMID:
26717247
43.

Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma.

Ophthalmic Oncology Task Force.

Ophthalmology. 2016 Jan;123(1):86-91. doi: 10.1016/j.ophtha.2015.09.014. Epub 2015 Oct 21.

44.

Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.

de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, van der Burg SH, Luyten GP, van Hall T, Jager MJ, van der Velden PA.

Oncotarget. 2015 Nov 10;6(35):37824-35. doi: 10.18632/oncotarget.5637.

45.

Radiation Treatment Affects Chromosome Testing in Uveal Melanoma.

Dogrusöz M, Kroes WG, van Duinen SG, Creutzberg CL, Versluis M, Bleeker JC, Marinkovic M, Luyten GP, Jager MJ.

Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5956-64. doi: 10.1167/iovs.15-17092.

PMID:
26393462
46.

The Champalimaud Vision Award: honouring basic and translational research.

Jager MJ.

Acta Ophthalmol. 2015 Sep;93(6):493-5. doi: 10.1111/aos.12767. No abstract available.

47.

Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism.

de Lange MJ, Razzaq L, Versluis M, Verlinde S, Dogrusöz M, Böhringer S, Marinkovic M, Luyten GP, de Keizer RJ, de Gruijl FR, Jager MJ, van der Velden PA.

PLoS One. 2015 Sep 14;10(9):e0138002. doi: 10.1371/journal.pone.0138002. eCollection 2015.

48.

EMT-associated factors promote invasive properties of uveal melanoma cells.

Asnaghi L, Gezgin G, Tripathy A, Handa JT, Merbs SL, van der Velden PA, Jager MJ, Harbour JW, Eberhart CG.

Mol Vis. 2015 Aug 25;21:919-29. eCollection 2015.

49.

Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines.

Refaian N, Schlereth SL, Koch KR, Notara M, Hos D, Mescher M, Iden S, Bosch JJ, Jager MJ, Cursiefen C, Heindl LM.

Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5691-7. doi: 10.1167/iovs.15-16829.

PMID:
26313304
50.

Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.

van Dijk EH, van Herpen CM, Marinkovic M, Haanen JB, Amundson D, Luyten GP, Jager MJ, Kapiteijn EH, Keunen JE, Adamus G, Boon CJ.

Ophthalmology. 2015 Sep;122(9):1907-16. doi: 10.1016/j.ophtha.2015.05.027. Epub 2015 Jun 26.

PMID:
26123090

Supplemental Content

Loading ...
Support Center